Table 1.
Cohort demographics
| RA+aTNF | RA+MTX | RA | Healthy Controls | |
|---|---|---|---|---|
| N | 61 | 70 | 33 | 97 |
| Age, mean +/- SD years | 55.4 +/- 12.3 | 58.4 +/-12.2 | 57.1 +/-13.8 | 39.8 +/- 13.6 |
| % female | 82% | 77% | 64% | 63% |
| Disease duration < 1 year | 5% | 17% | 45% | NA |
| Disease duration > 3 years | 93% | 60% | 47% | NA |
| Adalimumab n (%) | 9 (15) | NA | NA | NA |
| Infliximab n (%) | 17 (28) | NA | NA | NA |
| Etanercept n (%) | 35 (57) | NA | NA | NA |
| MTX n (%) | 49 (80) | 70 (100) | 0 (0) | NA |
| MTX, dose +/- SD mg/wk | 15.2 +/- 4.3 | 16.5 +/- 4.0 | NA | NA |
| corticosteroid n (%) | 18 (29.5) | 26 (37.1) | 10 (30.3) | NA |
| corticosteroid, dose +/- SD mg/d | 5.5 +/- 3.5 | 4.9 +/- 2.0 | 10.3 +/-6.1 | NA |
| ESR mean (range) | 21 (4-70) | 22 (2-83) | 20 (2-74) | NA |
| HAQ mean (range) | 0.71 (0.00-2.22) | 0.73 (0.00-2.75) | 0.46 (0.00-1.63) | NA |
| VAS mean (range) cm | 2.8 (0.0-9.8) | 3.3 (0.0-7.5) | 2.8 (0.0-7.1) | NA |
| Morning stiffness mean (range) min | 81 (0-780) | 104 (0-1440) | 59 (0-180) | NA |
| Race non Caucasian n (%) | 8 (13) | 6 (9) | 2 (6) | 12 (12) |
ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MTX, methotrexate; NA, not applicable; SD, standard deviation; VAS, visual analogue score.